beta-carotene and Hepatitis

beta-carotene has been researched along with Hepatitis* in 2 studies

Other Studies

2 other study(ies) available for beta-carotene and Hepatitis

Article	Year
Plasma ubiquinone to ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion. BioFactors (Oxford, England), 1999, Volume: 9, Issue:2-4 To assess the degree of oxidative stress, we measured plasma ubiquinone-10 percentage (%CoQ-10) in total amounts of ubiquinone-10 in patients with chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma, and in age-matched control subjects, %CoQ-10 values were 12.9 +/- 10.3 (n = 28), 10.6 +/- 6.8 (n = 28), 18.9 +/- 11.1 (n = 20), and 6.4 +/- 3.3 (n = 16), respectively, showing a significant increase in oxidative stress in patient groups as compared to control subjects. There were no differences in total amounts of ubiquinone-10 and ubiquinol-10 among the four groups. We next measured %CoQ-10 in plasmas obtained from nine patients treated with percutaneous transluminal coronary angioplasty (PTCA). Plasmas were collected when hospitalized, and at the time (0, 4, 8, 12, 16, and 20 hr, and 1, 2, 3, 4, and 7 days) after the PTCA. %CoQ-10 values before and right after PTCA were 9.9 +/- 2.8 and 11.4 +/- 2.0, respectively, reached a maximum (20-45) at 1 or 2 days later, and decreased to 7.9 +/- 2.7 at 7 days after PTCA, indicating an increase in oxidative stress in patients during coronary reperfusion. Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Ascorbic Acid; beta Carotene; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Carotenoids; Female; Hepatitis; Humans; Liver Cirrhosis; Liver Neoplasms; Lycopene; Male; Middle Aged; Oxidative Stress; Reference Values; Ubiquinone; Uric Acid; Vitamin E	1999
[Current approaches to using beta-carotenoids in chronic hepatitis in flight personnel]. Aviakosmicheskaia i ekologicheskaia meditsina = Aerospace and environmental medicine, 1996, Volume: 30, Issue:3 48 patients from flying personnel with chronic diseases of the liver have been studied. Considering poor effectiveness of the available hepatotropic drugs, a new B-caratinoid, veteron, was used at different daily doses. Findings of this study allowed us to draw inferences not only about more efficient clinical effect of this preparation beginning from a daily dose of 160 mg/day but also about its immunomodulating and pro-oxidant action. Thus, veteron is optimal for patients with chronic disorders of the immunologic and antioxidant systems and can be effectively used in treatment of these diseases. Topics: Adult; Antibody Formation; beta Carotene; Chronic Disease; Drug Evaluation; Hepatitis; Humans; Immunity, Cellular	1996

Article

Year

Plasma ubiquinone to ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion.

BioFactors (Oxford, England), 1999, Volume: 9, Issue:2-4

To assess the degree of oxidative stress, we measured plasma ubiquinone-10 percentage (%CoQ-10) in total amounts of ubiquinone-10 in patients with chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma, and in age-matched control subjects, %CoQ-10 values were 12.9 +/- 10.3 (n = 28), 10.6 +/- 6.8 (n = 28), 18.9 +/- 11.1 (n = 20), and 6.4 +/- 3.3 (n = 16), respectively, showing a significant increase in oxidative stress in patient groups as compared to control subjects. There were no differences in total amounts of ubiquinone-10 and ubiquinol-10 among the four groups. We next measured %CoQ-10 in plasmas obtained from nine patients treated with percutaneous transluminal coronary angioplasty (PTCA). Plasmas were collected when hospitalized, and at the time (0, 4, 8, 12, 16, and 20 hr, and 1, 2, 3, 4, and 7 days) after the PTCA. %CoQ-10 values before and right after PTCA were 9.9 +/- 2.8 and 11.4 +/- 2.0, respectively, reached a maximum (20-45) at 1 or 2 days later, and decreased to 7.9 +/- 2.7 at 7 days after PTCA, indicating an increase in oxidative stress in patients during coronary reperfusion.

Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Ascorbic Acid; beta Carotene; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Carotenoids; Female; Hepatitis; Humans; Liver Cirrhosis; Liver Neoplasms; Lycopene; Male; Middle Aged; Oxidative Stress; Reference Values; Ubiquinone; Uric Acid; Vitamin E

1999

[Current approaches to using beta-carotenoids in chronic hepatitis in flight personnel].

Aviakosmicheskaia i ekologicheskaia meditsina = Aerospace and environmental medicine, 1996, Volume: 30, Issue:3

48 patients from flying personnel with chronic diseases of the liver have been studied. Considering poor effectiveness of the available hepatotropic drugs, a new B-caratinoid, veteron, was used at different daily doses. Findings of this study allowed us to draw inferences not only about more efficient clinical effect of this preparation beginning from a daily dose of 160 mg/day but also about its immunomodulating and pro-oxidant action. Thus, veteron is optimal for patients with chronic disorders of the immunologic and antioxidant systems and can be effectively used in treatment of these diseases.

Topics: Adult; Antibody Formation; beta Carotene; Chronic Disease; Drug Evaluation; Hepatitis; Humans; Immunity, Cellular

1996